← Oncology Approval Tracker

FDA DECISION ·

Keytruda + chemotherapy

pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy · Merck

FDA approvalNew or expanded indicationEsophageal and gastroesophageal junction cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Patients with metastatic or locally advanced esophageal or gastroesophageal junction carcinoma who cannot undergo resection or definitive chemoradiation. The labeled junction tumors have an epicenter 1 to 5 centimeters above the junction.

LAMPGEN ANALYSIS

Why it matters

This adds a checkpoint inhibitor to chemotherapy in patients unsuitable for curative local treatment.

What research teams should watch

Capture the tumor epicenter and rationale for foregoing definitive local therapy.

PRIMARY RECORDS

Sources